Timothy Pluard

6.4k total citations · 1 hit paper
80 papers, 1.9k citations indexed

About

Timothy Pluard is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Timothy Pluard has authored 80 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 50 papers in Pulmonary and Respiratory Medicine and 20 papers in Cancer Research. Recurrent topics in Timothy Pluard's work include Advanced Breast Cancer Therapies (41 papers), HER2/EGFR in Cancer Research (32 papers) and Cancer Treatment and Pharmacology (27 papers). Timothy Pluard is often cited by papers focused on Advanced Breast Cancer Therapies (41 papers), HER2/EGFR in Cancer Research (32 papers) and Cancer Treatment and Pharmacology (27 papers). Timothy Pluard collaborates with scholars based in United States, Spain and United Kingdom. Timothy Pluard's co-authors include Olwen Hahn, Lisa A. Carey, Charles M. Perou, Donald A. Berry, Elisa Port, Mehra Golshan, George Somlo, Sara M. Tolaney, Eric P. Winer and William M. Sikov and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Timothy Pluard

74 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

2014 650 citations William M. Sikov, Donald A. Berry et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Timothy Pluard United States	20	1.3k	772	751	534	170	80	1.9k
Mafalda Oliveira Spain	24	1.5k 1.1×	893 1.2×	1.1k 1.4×	680 1.3×	187 1.1×	172	2.2k
Zhimin Shao China	22	1.1k 0.9×	557 0.7×	557 0.7×	516 1.0×	142 0.8×	90	1.8k
Ilenia Migliaccio Italy	23	1.2k 1.0×	583 0.8×	828 1.1×	828 1.6×	118 0.7×	64	2.1k
Manuel Ruíz‐Borrego Spain	19	1.3k 1.0×	771 1.0×	961 1.3×	447 0.8×	106 0.6×	97	1.9k
Yang Luo China	21	989 0.8×	529 0.7×	476 0.6×	371 0.7×	139 0.8×	135	1.5k
Jin‐Hee Ahn South Korea	25	938 0.7×	484 0.6×	821 1.1×	549 1.0×	126 0.7×	115	1.9k
Stephen P. Anthony United States	14	881 0.7×	603 0.8×	368 0.5×	482 0.9×	199 1.2×	53	1.5k
Eva Ciruelos Spain	15	1.5k 1.1×	936 1.2×	1.4k 1.8×	924 1.7×	185 1.1×	76	2.5k
Luigi Formisano Italy	25	1.1k 0.8×	494 0.6×	772 1.0×	1.1k 2.1×	159 0.9×	73	2.2k
Meritxell Bellet Spain	19	1.4k 1.1×	618 0.8×	988 1.3×	656 1.2×	102 0.6×	70	2.1k

Countries citing papers authored by Timothy Pluard

Since Specialization

Citations

This map shows the geographic impact of Timothy Pluard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Pluard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Pluard more than expected).

Fields of papers citing papers by Timothy Pluard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Pluard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Pluard. The network helps show where Timothy Pluard may publish in the future.

Co-authorship network of co-authors of Timothy Pluard

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy Pluard. A scholar is included among the top collaborators of Timothy Pluard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy Pluard. Timothy Pluard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Veenstra, David L., Adam Brufsky, Timothy Pluard, et al.. (2025). First-line cyclin-dependent kinase 4 and 6 inhibitors in combination with an aromatase inhibitor for HR+/HER2- metastatic breast cancer: A real-world cost-effectiveness assessment in a US Medicare-eligible population. Journal of Managed Care & Specialty Pharmacy. 31(10). 1039–1050.

Pluard, Timothy, et al.. (2025). Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2− Metastatic Breast Cancer. ClinicoEconomics and Outcomes Research. Volume 17. 247–264. 1 indexed citations

Rocque, Gabrielle B., Joanne L. Blum, Yan Ji, et al.. (2024). Abstract PO3-05-11: Enhancing the interpretation of real-world quality of life (QoL) in patients (pts) with hormone receptor positive human epidermal growth factor 2 negative (HR+/HER2−) advanced breast cancer (ABC) enrolled in the POLARIS trial. Cancer Research. 84(9_Supplement). PO3–5.

Hart, Lowell L., Seock‐Ah Im, Sara M. Tolaney, et al.. (2024). Abstract PS02-01: Efficacy, safety, and quality of life with ribociclib + endocrine therapy in elderly patients with HR+/HER2– advanced breast cancer across the MONALEESA-2, -3, and -7 trials. Cancer Research. 84(9_Supplement). PS02–1. 1 indexed citations

Hamilton, Erika, Timothy Pluard, Judy S. Wang, et al.. (2024). H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).. Journal of Clinical Oncology. 42(16_suppl). 1015–1015. 4 indexed citations

Goldfarb, Shari, Sarah Sammons, Jane Meisel, et al.. (2023). (114) Vaginal/Vulvar Symptoms with Lasofoxifene versus Fulvestrant in ESR1-mutated, ER+/HER2- Metastatic Breast Cancer Patients. The Journal of Sexual Medicine. 20(Supplement_2). 2 indexed citations

Lin, Nancy U., Virginia F. Borges, Manish R. Patel, et al.. (2023). 382MO Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer. Annals of Oncology. 34. S338–S338. 7 indexed citations

Ward, Christopher, et al.. (2023). P1.21-16 NSCLC Microenvironment Subtypes Correlate with Response and Survival to Immune Checkpoint Inhibitor Therapy. Journal of Thoracic Oncology. 18(11). S241–S241. 1 indexed citations

Abughanimeh, Omar, et al.. (2022). Hereditary Thrombophilia Testing Among Hospitalized Patients: Is It Warranted?. Cureus. 14(5). e24855–e24855. 1 indexed citations

10.

Rocque, Gabrielle B., Joanne L. Blum, Yan Ji, et al.. (2022). 266P Real-world quality of life (QoL) in patients with HR+/HER2-advanced breast cancer (ABC) treated with palbociclib: Final clinical outcome assessment (COA) analysis from POLARIS. Annals of Oncology. 33. S659–S659. 2 indexed citations

11.

Tan, Antoinette R., Gail S. Wright, Anu Thummala, et al.. (2021). Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study. Clinical Cancer Research. 28(4). 629–636. 28 indexed citations

12.

Bahaj, Waled, Kevin F. Kennedy, Timothy Pluard, et al.. (2018). Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers. Molecular Cancer Therapeutics. 17(5). 1123–1132. 19 indexed citations

13.

Pistilli, Barbara, Timothy Pluard, Ander Urruticoechea, et al.. (2017). Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Research and Treatment. 168(2). 357–364. 50 indexed citations

14.

Rugo, Hope S., Lasika Seneviratne, J. Thaddeus Beck, et al.. (2017). Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. The Lancet Oncology. 18(5). 654–662. 145 indexed citations

15.

Cynthia, X., César Sánchez, Feng Gao, et al.. (2016). A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer. Clinical Cancer Research. 22(11). 2650–2658. 62 indexed citations

16.

Cynthia, X., Jingqin Luo, Michael Naughton, et al.. (2015). A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer. Clinical Cancer Research. 22(7). 1583–1591. 77 indexed citations

17.

Xiang, Jingyu, Michelle A. Hurchla, Francesca Fontana, et al.. (2015). CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 14(11). 2473–2485. 49 indexed citations

18.

Sikov, William M., Donald A. Berry, Charles M. Perou, et al.. (2014). Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology. 33(1). 13–21. 650 indexed citations breakdown →

19.

Saura, Cristina, José Á. García-Sáenz, Binghe Xu, et al.. (2014). Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. Journal of Clinical Oncology. 32(32). 3626–3633. 103 indexed citations

20.

Naughton, Michael, Catherine Van Poznak, Jochen G. Schneider, et al.. (2013). A Randomized Phase II Trial Investigating the Effect of Platelet Function Inhibition on Circulating Tumor Cells in Patients With Metastatic Breast Cancer. Clinical Breast Cancer. 13(6). 409–415. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact